Dr. Florian Robert
Florian considers himself a versatile researcher, putting effort and skills where he is most needed, especially in Bio-Medical Research. He thus studies various diseases, to provide significant assets to further treat patients with new and innovative medicine.
Florian obtained his Ph.D. in 2019 at the CEA of Grenoble, FRANCE. He setup a High-Throughput Screening assay to reposition FDA/EMA approved chemicals to rescue depleted BMP9/BMP10 signalling pathways; in both Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia (Rendu-Osler disease).
In 2021, Florian joined Pr. Andrew Lever’s Team at The Department of Clinical Medicine, Addenbrooke’s Hospital of Cambridge to investigate SAMHD1 polymorphisms in HIV-1 patients, and later propose new ways of diagnosis and personalised medicine.
After Pr. Lever’s lab closure in March 2022, Florian got a once in a lifetime chance to join Pr. Nik-Zainal’s team at the Department of Medical Genetics in 2022, where he will decipher dNTPs-related signatures in cancer.
If you ever want to talk music, Arda stuff, or even NFL, he’s your man. Go Packers.
Published Works
- Tu, L., Desroches-Castan, A., Mallet, C., Guyon, L., Cumont, A., Phan, C., Robert, F., Thuillet, R., Bordenave, J., Sekine, A., Huertas, A., Ritvos, O., Savale, L., Feige, J. J., Humbert, M., Bailly, S., & Guignabert, C. (2019). Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circulation research, 124(6), 846–855. https://doi.org/10.1161/CIRCRESAHA.118.313356
- Robert, F., Desroches-Castan, A., Bailly, S., Dupuis-Girod, S., & Feige, J. J. (2020). Future treatments for hereditary hemorrhagic telangiectasia. Orphanet journal of rare diseases, 15(1), 4. https://doi.org/10.1186/s13023-019-1281-4
Contact Us
Prof. Serena Nik-Zainal
Early Cancer Institute
University of Cambridge
Hutchison Research Centre
Box 197
Cambridge Biomedical Campus
Cambridge
United Kingdom
CB2 0XZ